
Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
These are the top 200 brand and generic drugs by wholesale acquisition cost (WAS) dollars used in hospitals last year. The data were provided by Wolters Kluwer Health, Pharmaceutical Audit Suite (PHAST), January to December 2006.






